Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study.
We showed earlier that activating autoantibodies against the angiotensin II type 1 (AT(1)) receptor (AT1-AA) circulate in preeclamptic women. They may be involved in the pathogenesis of preeclampsia. Protein alignment suggests that the binding site for AT1-AAs is highly homologous to the capsid prot...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
2009
|
| _version_ | 1797077931793580032 |
|---|---|
| author | Herse, F Verlohren, S Wenzel, K Pape, J Muller, D Modrow, S Wallukat, G Luft, F Redman, C Dechend, R |
| author_facet | Herse, F Verlohren, S Wenzel, K Pape, J Muller, D Modrow, S Wallukat, G Luft, F Redman, C Dechend, R |
| author_sort | Herse, F |
| collection | OXFORD |
| description | We showed earlier that activating autoantibodies against the angiotensin II type 1 (AT(1)) receptor (AT1-AA) circulate in preeclamptic women. They may be involved in the pathogenesis of preeclampsia. Protein alignment suggests that the binding site for AT1-AAs is highly homologous to the capsid protein VP2 of parvovirus B19. We performed a prospective, nested, case-control study of 30 gestational age-matched women with preeclampsia and 30 normotensive pregnant women. We measured AT1-AA, soluble fms-like tyrosine kinase 1 (sFlt-1), and serum immunoglobulin G against parvovirus B19 proteins. AT1-AAs were present in 70% of preeclamptic patients and absent in 80% of controls. Prediction by AT1-AA was improved in late-onset preeclampsia. The discrimination for sFlt-1 was 96%. We did not find an interaction between sFlt-1 and AT1-AA. A human monoclonal immunoglobulin G antibody against parvovirus B19 VP2-protein showed a positive reaction in the AT1-AA bioassay, which could be blocked by an AT(1) receptor blocker, as well as by the epitope amino acid sequence. Immunoglobulin G against parvovirus B19 proteins was similarly distributed between preeclamptic patients and controls and had no significant importance. We detected significantly more AT1-AA in women with an immune response corresponding with parvovirus B19 infection corresponding with a distant viral infection associated with virus elimination. We concluded that AT1-AAs were common in patients with preeclampsia in a prospective case-control study, although sFlt-1 was a superior biomarker. AT1-AA may represent a better marker for late disease, whereas sFlt1 is a better marker for early onset disease. |
| first_indexed | 2024-03-07T00:25:07Z |
| format | Conference item |
| id | oxford-uuid:7de12cbc-e10d-4c61-8e85-ffdd4717d20b |
| institution | University of Oxford |
| last_indexed | 2024-03-07T00:25:07Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:7de12cbc-e10d-4c61-8e85-ffdd4717d20b2022-03-26T21:06:32ZPrevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study.Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:7de12cbc-e10d-4c61-8e85-ffdd4717d20bSymplectic Elements at Oxford2009Herse, FVerlohren, SWenzel, KPape, JMuller, DModrow, SWallukat, GLuft, FRedman, CDechend, RWe showed earlier that activating autoantibodies against the angiotensin II type 1 (AT(1)) receptor (AT1-AA) circulate in preeclamptic women. They may be involved in the pathogenesis of preeclampsia. Protein alignment suggests that the binding site for AT1-AAs is highly homologous to the capsid protein VP2 of parvovirus B19. We performed a prospective, nested, case-control study of 30 gestational age-matched women with preeclampsia and 30 normotensive pregnant women. We measured AT1-AA, soluble fms-like tyrosine kinase 1 (sFlt-1), and serum immunoglobulin G against parvovirus B19 proteins. AT1-AAs were present in 70% of preeclamptic patients and absent in 80% of controls. Prediction by AT1-AA was improved in late-onset preeclampsia. The discrimination for sFlt-1 was 96%. We did not find an interaction between sFlt-1 and AT1-AA. A human monoclonal immunoglobulin G antibody against parvovirus B19 VP2-protein showed a positive reaction in the AT1-AA bioassay, which could be blocked by an AT(1) receptor blocker, as well as by the epitope amino acid sequence. Immunoglobulin G against parvovirus B19 proteins was similarly distributed between preeclamptic patients and controls and had no significant importance. We detected significantly more AT1-AA in women with an immune response corresponding with parvovirus B19 infection corresponding with a distant viral infection associated with virus elimination. We concluded that AT1-AAs were common in patients with preeclampsia in a prospective case-control study, although sFlt-1 was a superior biomarker. AT1-AA may represent a better marker for late disease, whereas sFlt1 is a better marker for early onset disease. |
| spellingShingle | Herse, F Verlohren, S Wenzel, K Pape, J Muller, D Modrow, S Wallukat, G Luft, F Redman, C Dechend, R Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. |
| title | Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. |
| title_full | Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. |
| title_fullStr | Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. |
| title_full_unstemmed | Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. |
| title_short | Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. |
| title_sort | prevalence of agonistic autoantibodies against the angiotensin ii type 1 receptor and soluble fms like tyrosine kinase 1 in a gestational age matched case study |
| work_keys_str_mv | AT hersef prevalenceofagonisticautoantibodiesagainsttheangiotensiniitype1receptorandsolublefmsliketyrosinekinase1inagestationalagematchedcasestudy AT verlohrens prevalenceofagonisticautoantibodiesagainsttheangiotensiniitype1receptorandsolublefmsliketyrosinekinase1inagestationalagematchedcasestudy AT wenzelk prevalenceofagonisticautoantibodiesagainsttheangiotensiniitype1receptorandsolublefmsliketyrosinekinase1inagestationalagematchedcasestudy AT papej prevalenceofagonisticautoantibodiesagainsttheangiotensiniitype1receptorandsolublefmsliketyrosinekinase1inagestationalagematchedcasestudy AT mullerd prevalenceofagonisticautoantibodiesagainsttheangiotensiniitype1receptorandsolublefmsliketyrosinekinase1inagestationalagematchedcasestudy AT modrows prevalenceofagonisticautoantibodiesagainsttheangiotensiniitype1receptorandsolublefmsliketyrosinekinase1inagestationalagematchedcasestudy AT wallukatg prevalenceofagonisticautoantibodiesagainsttheangiotensiniitype1receptorandsolublefmsliketyrosinekinase1inagestationalagematchedcasestudy AT luftf prevalenceofagonisticautoantibodiesagainsttheangiotensiniitype1receptorandsolublefmsliketyrosinekinase1inagestationalagematchedcasestudy AT redmanc prevalenceofagonisticautoantibodiesagainsttheangiotensiniitype1receptorandsolublefmsliketyrosinekinase1inagestationalagematchedcasestudy AT dechendr prevalenceofagonisticautoantibodiesagainsttheangiotensiniitype1receptorandsolublefmsliketyrosinekinase1inagestationalagematchedcasestudy |